Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback